ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.66
1.00%
US Tech 100
20,877.20
1.72%
다우존스 지수
43,487.83
0.78%
Bitcoin
103,546.57
-0.57%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Kyverna Therapeutics Inc (KYTX) 시세

Kyverna Therapeutics Inc

Kyverna Therapeutics Inc (KYTX)

NASDAQ
3.33
-0.10
(-2.92%)
마감 18 1월 6:00AM
15분 지연
3.36
0.03
(0.90%)
시간외 거래: 9:59AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
3.36
매수가
3.35
매도가
3.60
거래량
183,493
3.295 일간 변동폭 3.525
3.24 52주 범위 35.01
market_cap
145.057M
전일 종가
3.43
개장가
3.51
최근 거래 시간
200
@
3.36
(formt)
마지막 거래 시간
재정 규모
US$ 626,552
VWAP
3.4146
평균 볼륨(3m)
321,974
발행 주식
43,171,612
배당수익률
-
주가수익률
-2.39
주당순이익(EPS)
-1.4
매출
-
순이익
-60.37M

Kyverna Therapeutics Inc 정보

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin... Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna's pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
kyvernatx.com
본부
Dover, Delaware, USA
설립됨
-
Kyverna Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker KYTX. The last closing price for Kyverna Therapeutics was US$3.43. Over the last year, Kyverna Therapeutics shares have traded in a share price range of US$ 3.24 to US$ 35.01.

Kyverna Therapeutics currently has 43,171,612 shares in issue. The market capitalisation of Kyverna Therapeutics is US$148.08 million. Kyverna Therapeutics has a price to earnings ratio (PE ratio) of -2.39.

KYTX 최신 뉴스

추가 뉴스

Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights - KYTX

Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights - KYTX PR Newswire NEW YORK, Jan. 16...

16 1월 2025
PR Newswire (US)

Form 8-K - Current report

13 1월 2025
Edgar (US Regulatory)

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire EMERYVILLE, Calif., Jan. 13, 2025 Extending...

13 1월 2025
PR Newswire (US)

Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, Jan. 13, 2025 NEW YORK, Jan. 13, 2025 /PRNewswire/...

13 1월 2025
PR Newswire (US)

The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX

The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX PR Newswire NEW YORK, Jan. 9, 2025...

09 1월 2025
PR Newswire (US)

Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors

SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets...

08 1월 2025
GlobeNewswire Inc.

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference PR Newswire EMERYVILLE, Calif., Jan. 6, 2025 EMERYVILLE, Calif., Jan. 6, 2025 /PRNewswire/ -- Kyverna...

07 1월 2025
PR Newswire (US)

The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX

The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX PR Newswire NEW YORK, Jan. 6, 2025...

06 1월 2025
PR Newswire (US)

Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) should contact The Gross Law Firm about pending Class Action - KYTX

Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) should contact The Gross Law Firm about pending Class Action - KYTX PR Newswire NEW YORK, Jan. 2, 2025 NEW YORK, Jan. 2, 2025...

03 1월 2025
PR Newswire (US)

February 7, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against KYTX

February 7, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against KYTX PR Newswire NEW YORK, Dec. 30, 2024 NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues...

30 12월 2024
PR Newswire (US)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.29-7.945205479453.653.673.242980393.36622733CS
4-0.45-11.8110236223.814.263.243250903.76068302CS
12-1.66-33.06772908375.027.23.243219744.56562321CS
26-7.5-69.060773480710.8611.313.243654005.93711943CS
52-30.89-90.189781021934.2535.013.2444816111.9377551CS
156-30.89-90.189781021934.2535.013.2444816111.9377551CS
260-30.89-90.189781021934.2535.013.2444816111.9377551CS

KYTX - Frequently Asked Questions (FAQ)

What is the current Kyverna Therapeutics share price?
The current share price of Kyverna Therapeutics is US$ 3.36
How many Kyverna Therapeutics shares are in issue?
Kyverna Therapeutics has 43,171,612 shares in issue
What is the market cap of Kyverna Therapeutics?
The market capitalisation of Kyverna Therapeutics is USD 148.08M
What is the 1 year trading range for Kyverna Therapeutics share price?
Kyverna Therapeutics has traded in the range of US$ 3.24 to US$ 35.01 during the past year
What is the PE ratio of Kyverna Therapeutics?
The price to earnings ratio of Kyverna Therapeutics is -2.39
What is the reporting currency for Kyverna Therapeutics?
Kyverna Therapeutics reports financial results in USD
What is the latest annual profit for Kyverna Therapeutics?
The latest annual profit of Kyverna Therapeutics is USD -60.37M
What is the registered address of Kyverna Therapeutics?
The registered address for Kyverna Therapeutics is 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
What is the Kyverna Therapeutics website address?
The website address for Kyverna Therapeutics is kyvernatx.com
Which industry sector does Kyverna Therapeutics operate in?
Kyverna Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

토론

전체 피드 보기
nwtf nwtf 5 분 전
PJ is nothing more than a troll. Same posts and lies time and time again.
ERHE
kund kund 6 분 전
Brand new account , welcome to WGT club.
AVXL
fuagf fuagf 8 분 전
Agree it should be an easy no, yet according to the articles he is already saying one thing in public and another in private. Surely in the hearing he would tell the Senators what they wanted to hear. Bondi refused to say Biden won the 2020 election. Bondi says, emphatically, politics would not pl
Richie R Richie R 8 분 전
Who is going to jump in the drivers seat and head towards the dollars???
flipper44 flipper44 10 분 전
I think this is one of three reasons Hindenburg closed shop.
NWBO
Researchfyi Researchfyi 12 분 전
“Maybe if the bashers didn’t fling their BS 24/7 on the stock boards it would be different.

Chalk it up for the BSers!”

A classic case of a disconnect from reality.

Chalk it up to basher derangement syndrome. :)
LQMT
Lime Time Lime Time 13 분 전
lol basher turds don't understand how this works. CEO has COMMON Shares at about .00045 so it will not split under that. Watch for the run up this year. These people who claim to understand OTC stocks on OTC Markets have not a clue about how it works lolol
BCAP
dinogreeves dinogreeves 13 분 전
https://www.ndtvprofit.com/business/hindenburg-shutdown-nate-anderson-sec-scrutiny
SMCI
littlejohn littlejohn 16 분 전
Around $33 starts new short squeeze area

now since the 11/15/24 low...

https://www.barchart.com/stocks/quotes/SMCI/interactive-chart

We are at the mercy of the big fundies

that control most of the trading float...

Sadly, ma
SMCI
XMaster2023 XMaster2023 17 분 전
RobotDroid you’re working late tonight. Must live in CA.
NWBO
dinogreeves dinogreeves 22 분 전
Very odd, the way NBIS and SMC*I trading, however I do understand SMC*I leaving some traders, trading in and out and weary of the time line of the audit report. We have had massive up days with the general market especially today and both were down. This one doesn't get too much coverage with the
NBIS
Jollibee Jollibee 25 분 전
Fist time in 2 years I’ve been on this position. Too bad it’s in my Roth IRA so I can’t play with it, but I’ll definitely flip it into either XDTE or YBTC, and take the weekly dividend and not reinvest. Dividend harvesting time, I’m eyeing quantum and evtl stocks for long game plays. And the APPS st
FDCT
AlwaysOptimistic AlwaysOptimistic 27 분 전
I also think there is enough room and enough investors dollars out there for all things tech (AI, quantum, bio tech, Fortine 500 and others). Good chance there will be more foreign investment coming in with the change in admins for a more business friendly environment for foreign investment dollars.
IONQ
Dodger1 Dodger1 28 분 전
https:/ /www.juliawalck.com/shop/p/the-most-important-meal-art-print
AABB
Dodger1 Dodger1 32 분 전
https ://www.juliawalck.com/shop/p/egg-on-your-face-art-print

$AABB
AABB
TightCoil TightCoil 33 분 전
We have to be wary of a Release with Conditions -
We must Fight, Fight, Fight For, INSIST ON:

UNCONDITIONAL RELEASE

And until we're guaranteed an Unconditional Release
we must stay Afraid, Very Afraid
FNMA
santafe2 santafe2 33 분 전
While all the focus is on tech criminals the real problem may be the crypto Ponzi scheme. They spent reportedly $170MM to get him elected. There's a reason he loves the poorly educated. This is the message heard loud and clear by everyone from banking to investment and, of course, every criminal in
quester614 quester614 37 분 전
MovyChem was a SCAM company along with Xeriant SRO. MovyChem EU is gone . No website for either. A company that took 20 years to develop Retacell just disappears. I have shown before that Xeriant SRO & MovyChem were started by Vladimír Bíža who can be tracked back to Aegea Inc/ Futureland SCAM He al
XERI
3331 3331 38 분 전
BIEL: HUGE HIT IN TAIWAN!
https://www.actipatchtw.com/general-1
dinogreeves dinogreeves 40 분 전
Once they kill all the options by the dead line, this will run. Market makers are begging for mercy they don't report before the deadline, they have probably colluded with the insiders too, it is plausible. The quote below is from someone on Stocktwits. Essentially I am not to only one with commo
SMCI
Werbe Werbe 43 분 전
Everyone that posts here start with some extraordinary story of upbringing or some sort of passive social shout.  Anyone a high-school dropout or start from welfare?  
CrypticDomain141 CrypticDomain141 45 분 전
I’ve done my research and I’m long.

I don’t understand why everyone is so shocked that this is still volatile at this time. It doesn’t have any revenue yet, and it doesn’t have a big pharm partner….yet.

But from the clinical trials it seems they’ve got the goods. The C
AVXL
Drugdoctor Drugdoctor 48 분 전
Here is our CEO's stock chart pattern... Soon we will see $SRNW sporting the same pattern.

https://investorshub.advfn.com/uimage/uploads/2025/1/17/yrkgpGVSI_1-17.png
SRNW
AlwaysOptimistic AlwaysOptimistic 49 분 전
I also saw that. Of course Chambers would take that position. He has a lot of capital invested in AI and other tech with his venture funding group (JC2 Ventures) and a lot to lose if investors siphon money away from AI in to quantum. Just like NVDIA. This too shall pass IMO.
IONQ

최근 히스토리

NASDAQ
KYTX
Kyverna Therapeutics
LSE
0R0T
Amgen
ASX
FSIGA
Convert Bond 5.50% 01-10...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유